132 related articles for article (PubMed ID: 26888730)
1. Acknowledging unreported problems with active surveillance for prostate cancer: a prospective single-centre observational study.
Hefermehl LJ; Disteldorf D; Lehmann K
BMJ Open; 2016 Feb; 6(2):e010191. PubMed ID: 26888730
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
[TBL] [Abstract][Full Text] [Related]
3. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project.
Postema AW; De Reijke TM; Ukimura O; Van den Bos W; Azzouzi AR; Barret E; Baumunk D; Blana A; Bossi A; Brausi M; Coleman JA; Crouzet S; Dominguez-Escrig J; Eggener S; Ganzer R; Ghai S; Gill IS; Gupta RT; Henkel TO; Hohenfellner M; Jones JS; Kahmann F; Kastner C; Köhrmann KU; Kovacs G; Miano R; van Moorselaar RJ; Mottet N; Osorio L; Pieters BR; Polascik TJ; Rastinehad AR; Salomon G; Sanchez-Salas R; Schostak M; Sentker L; Tay KJ; Varkarakis IM; Villers A; Walz J; De la Rosette JJ
World J Urol; 2016 Oct; 34(10):1373-82. PubMed ID: 26892160
[TBL] [Abstract][Full Text] [Related]
4. Predictive Factors for Reclassification and Relapse in Prostate Cancer Eligible for Active Surveillance: A Systematic Review and Meta-analysis.
Petrelli F; Vavassori I; Cabiddu M; Coinu A; Ghilardi M; Borgonovo K; Lonati V; Barni S
Urology; 2016 May; 91():136-42. PubMed ID: 26896733
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.
Cole AI; Morgan TM; Spratt DE; Palapattu GS; He C; Tomlins SA; Weizer AZ; Feng FY; Wu A; Siddiqui J; Chinnaiyan AM; Montgomery JS; Kunju LP; Miller DC; Hollenbeck BK; Wei JT; Mehra R
J Urol; 2016 Aug; 196(2):405-11. PubMed ID: 26920466
[TBL] [Abstract][Full Text] [Related]
6. Questions and answers on prostate multiparameter magnetic resonance imaging: Everything a urologist should know.
Catalá V; Salas D; Esquena S; Mateu S; Algaba F; Palou J; de la Torre P
Actas Urol Esp; 2016; 40(6):339-52. PubMed ID: 26920095
[TBL] [Abstract][Full Text] [Related]
7. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
[TBL] [Abstract][Full Text] [Related]
8. The Utility of Molecular Imaging in Prostate Cancer.
Leiblich A; Stevens D; Sooriakumaran P
Curr Urol Rep; 2016 Mar; 17(3):26. PubMed ID: 26894753
[TBL] [Abstract][Full Text] [Related]
9. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
[TBL] [Abstract][Full Text] [Related]
10. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Geethakumari PR; Cookson MS; Kelly WK;
Oncology (Williston Park); 2016 Feb; 30(2):187-95, 199. PubMed ID: 26888794
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric MRI of the anterior prostate gland: clinical-radiological-histopathological correlation.
Moosavi B; Flood TA; Al-Dandan O; Breau RH; Cagiannos I; Morash C; Malone SC; Schieda N
Clin Radiol; 2016 May; 71(5):405-17. PubMed ID: 26888762
[TBL] [Abstract][Full Text] [Related]
12. Current status of active surveillance in prostate cancer.
Chung MS; Lee SH
Investig Clin Urol; 2016 Jan; 57(1):14-20. PubMed ID: 26966722
[TBL] [Abstract][Full Text] [Related]
13. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.
Loeb S; Walter D; Curnyn C; Gold HT; Lepor H; Makarov DV
J Urol; 2016 Sep; 196(3):721-6. PubMed ID: 26946161
[TBL] [Abstract][Full Text] [Related]
14. Active surveillance in Canadian men with low-grade prostate cancer.
Cristea O; Lavallée LT; Montroy J; Stokl A; Cnossen S; Mallick R; Fergusson D; Momoli F; Cagiannos I; Morash C; Breau RH
CMAJ; 2016 May; 188(8):E141-E147. PubMed ID: 26927971
[TBL] [Abstract][Full Text] [Related]
15. Favorable vs Unfavorable Intermediate-Risk Prostate Cancer: A Review of the New Classification System and Its Impact on Treatment Recommendations.
Serrano NA; Anscher MS
Oncology (Williston Park); 2016 Mar; 30(3):229-36. PubMed ID: 26984216
[TBL] [Abstract][Full Text] [Related]
16. Prospective Quality of Life in Men Choosing Active Surveillance Compared to Those Biopsied but not Diagnosed with Prostate Cancer.
Pham KN; Cullen J; Hurwitz LM; Wolff EM; Levie KE; Odem-Davis K; Banerji JS; Rosner IL; Brand TC; L'Esperance JO; Sterbis JR; Porter CR
J Urol; 2016 Aug; 196(2):392-8. PubMed ID: 26976206
[TBL] [Abstract][Full Text] [Related]
17. Active surveillance for prostate cancer: current evidence and contemporary state of practice.
Tosoian JJ; Carter HB; Lepor A; Loeb S
Nat Rev Urol; 2016 Apr; 13(4):205-15. PubMed ID: 26954332
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification system and pattern of relapse in patients treated with adjuvant radiotherapy after radical prostatectomy.
Levis M; Guarneri A; Giaj Levra N; Spratt DE; Bartoncini S; Munoz F; Trino E; Botticella A; Arcadipane F; Ricardi U
Tumori; 2016 Jun; 2016(3):323-9. PubMed ID: 27002951
[TBL] [Abstract][Full Text] [Related]
19. New developments in prostate cancer biomarkers.
Martin NE
Curr Opin Oncol; 2016 May; 28(3):248-52. PubMed ID: 26974844
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
